Immunovant, Inc. (IMVT) Financial Statements
Free cash flow over the same period: -$407.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMVTImmunovant, Inc.Follow IMVT — free
—
Price chart with a free account
- Market cap
- 5.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Mar 20 | FY2021 Mar 21 | FY2022 Mar 22 | FY2023 Mar 23 | FY2024 Mar 24 | FY2025 Mar 25 | FY2026 Mar 26 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | 47.9 | 68.6 | 101.8 | 160.3 | 212.9 | 360.9 | 456.7 | 498.1 | |
| Pre-tax income | -66.3 | -107.8 | -156.8 | -211.0 | -258.8 | -412.9 | -505.4 | -538.9 | |
| Income tax | 0.1 | -0.4 | -0.1 | 0.0 | 0.6 | 0.9 | 0.2 | -0.7 | |
| Net income | -66.4 | -107.4 | -156.7 | -211.0 | -259.3 | -413.8 | -505.6 | -538.2 | |
| Diluted EPS ($) | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 | -2.62 | |
| Diluted shares (mn) | — | — | 109.7 | 123.1 | 138.1 | 151.6 | 182.4 | — |
USD millions · SEC XBRL
Immunovant, Inc. — questions
- What is Immunovant, Inc.'s net income?
- -$538.2M over the twelve months to 2026-06-30.
- What is Immunovant, Inc.'s free cash flow?
- -$407.3M over the twelve months to 2026-06-30.
- What are Immunovant, Inc.'s diluted earnings per share?
- $-2.62 over the twelve months to 2026-06-30.
Every figure on this page comes from Immunovant, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.